Authors: Kiprov DD, Herskowitz A, Kim D, Lieb M, Liu C, Watanabe E

PMID: 35464182 PMCID: PMC9021669 DOI: 10.12688/f1000research.74534.2


Many patients with COVID-19 experience a range of debilitating symptoms months after being infected, a syndrome termed long-haul COVID. A 68-year-old male presented with lung opacity, fatigue, physical and cognitive weaknesses, loss of smell and lymphocytopenia. After rounds of therapeutic plasma exchange (TPE), the patient returned to normal activities and work. Mechanistically in the patient’s peripheral blood mononuclear cells (PBMCs), markers of inflammatory macrophages diminished and markers of lymphocytes, including natural killer (NK) cells and cytotoxic CD8 T-cells, increased. Circulating inflammatory proteins diminished, while positive regulators of tissue repair increased. This case study suggests that TPE has the capacity to treat long-haul COVID.

Keywords: Immunomodulation; Long Haul Covid19; adaptive immunity; inflammation; leukocyute subsets; plasmapheresis; proteomics.